Abstract
After multiple SARS-CoV2 outbreaks in 2020 and a population seropositivity of about 50%, Delhi was overwhelmed by the fourth wave. Multi-modal data, including genomic surveillance, shows that a controlled phase characterized by Alpha variant (B.1.1.7) dominance, became uncontrollable during its displacement by the new Delta variant (B.1.617.2). Bayesian modeling supports a combination of 40-60% increased transmissibility of the Delta variant and 10-50% reduction in immunity elicited by prior infection. A cohort with 45% seropositivity in March, showed 85% positivity in June 2021, with 14% reinfection based on uptick in titers after decline. High transmissibility and evasion of prior immunity by the Delta variant, coupled to social behavior that promoted transmission, led to the overwhelming pandemic outbreak in Delhi. This may become a global pattern.
One-Sentence Summary The Delta variant of SARS-CoV2, is extremely transmissible and can evade immunity elicited by infections of prior lineages, leading to severe outbreaks in regions with high seropositivity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
List of authors updated along with the supplementary figures.
Data Availability
Sequence data is being continuously uploaded on the GISAID.
